Eupraxia Pharmaceuticals (EPRX) vs Neurogene (NGNE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Eupraxia Pharmaceuticals (EPRX) has outperformed Neurogene (NGNE) over the past year, gaining 29.2% versus a gain of 2.6%. Neurogene is the larger company by market cap ($530.3 million vs $500.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EPRX | NGNE |
|---|---|---|
| Share price | $7.57 | $26.50 |
| Market cap | $500.18M | $530.30M |
| 1-day change | -2.70% | +2.44% |
| YTD return | +3.05% | +28.64% |
| 1-year return | +29.24% | +2.59% |
| 5-year return | — | -81.65% |
| EPS (TTM) | $-1.02 | $-5.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.32 | $43.66 |
| 52-week low | $5.25 | $15.93 |
| Distance from 52-week high | -18.78% | -39.30% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +115.98% | +193.89% |
| Average volume | 575.10K | 247.13K |
| Shares outstanding | 66.07M | 20.01M |
| Employees | 49 | 131 |
| Sector | Health Care | Healthcare |
| Industry | Pharmaceuticals and Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EPRX has outperformed NGNE by 26.6 percentage points over the past year.
- The two companies sit in different sectors: Eupraxia Pharmaceuticals in Health Care and Neurogene in Healthcare.
About Eupraxia Pharmaceuticals
EPRX stock →Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need.
Health Care · Pharmaceuticals and Biotechnology · 49 employees
About Neurogene
NGNE stock →Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.
Healthcare · Biotechnology · 131 employees
EPRX vs NGNE FAQ
Which is bigger, Eupraxia Pharmaceuticals or Neurogene?
Neurogene (NGNE) is larger, with a market capitalization of $530.30M compared with $500.18M for Eupraxia Pharmaceuticals (EPRX).
Which stock has performed better over the past year, EPRX or NGNE?
EPRX returned +29.24% over the past 12 months, compared with +2.59% for NGNE (price return, excluding dividends). Past performance does not predict future results.
Are Eupraxia Pharmaceuticals and Neurogene in the same industry?
No. Eupraxia Pharmaceuticals is in the Health Care sector, while Neurogene is in Healthcare.